サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1678794

ラベルフリー検出の世界市場-2025-2033

Global Label-Free Detection Market - 2025-2033

出版日
ページ情報
英文 220 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ラベルフリー検出の世界市場-2025-2033
出版日: 2025年03月11日
発行: DataM Intelligence
ページ情報: 英文 220 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のラベルフリー検出市場は、2024年に6億4,483万米ドルに達し、2033年には12億5,149万米ドルに達すると予測され、予測期間2025-2033年のCAGRは7.5%で成長します。

ラベルフリー検出は、蛍光標識、放射性標識、酵素標識を必要とせずに分子の物理的特性の変化を測定する高度な分析技術です。結合速度、親和性、濃度に関するリアルタイムデータを提供するため、創薬、リード最適化、バイオ医薬品研究に広く利用されています。ワークフローを合理化し、アッセイ開発時間を短縮し、最小限のサンプル調製で複雑な生物学的サンプルの分析を可能にします。

市場力学：

促進要因と抑制要因

高度な創薬・開発プロセスに対する需要の高まり

ラベルフリー検出市場は、先進的な創薬・製品開発プロセスに対する需要の高まりによって牽引されています。製薬企業やバイオテクノロジー企業は、生体分子間相互作用をリアルタイムで正確に測定し、データの質を向上させ、ラベル干渉を減らすために、これらの技術を好んで使用しています。バイオ医薬品、バイオシミラー、個別化医療への注目は、複雑な生体分子や標的治療の詳細な分析を可能にするこれらの技術の採用を加速しています。

さらに、ラベルフリー検出技術は、アーチファクトを低減した生物学的に関連性の高いデータを提供することで、創薬に革命をもたらしています。これらの方法は、色素やタグ、遺伝子組み換え細胞を必要としないため、ネイティブな細胞で生物学的相互作用をより正確に表現することができます。また、感度の向上、リアルタイムの動態、マルチターゲットプロファイリングも可能です。活用領域には、表現型スクリーニング、標的の同定と認証、ヒット・ツー・リード最適化、毒性評価などが含まれます。

限られた感度と検出範囲

ラベルフリー検出技術は、感度や検出範囲が限られているため、市場において課題に直面しています。これらのシステムはリアルタイム分析を提供しますが、特に複雑な生物学的サンプルにおいて、低存在量の生体分子や弱い分子間相互作用を検出する際に妥協する可能性があります。これは、早期のバイオマーカー探索、診断、薬剤スクリーニングのような重要なアプリケーションにおける精度と信頼性に影響します。従来の標識検出法が依然として好まれ、超高感度検出アプリケーションにおけるラベルフリー技術の採用が制限される可能性があります。

目次

第1章 分析手法と分析範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 高度な医薬品の発見と開発プロセスに対する需要の高まり
    • 抑制要因
      • 限られた感度と検出範囲
    • 機会
    • 影響分析

第5章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と主要企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の研究
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析：ベストケース・ベースケース・ワーストケースの予測
  • 価格分析と価格市場力学
  • キーオピニオンリーダー (KOL)

第6章 製品種類別

  • 装置
  • 消耗品
  • ソフトウェア・サービス

第7章 技術別

  • 表面プラズモン共鳴（SPR）
  • バイオレイヤー干渉法（BLI）
  • 等温滴定熱量測定法（ITC）
  • 示差走査熱量測定法（DSC）
  • その他

第8章 用途別

  • 創薬・医薬品開発
  • 動力額と熱力学の結合
  • ヒット確認・リード生成
  • 内因性受容体の検出
  • その他

第9章 エンドユーザー別

  • 製薬・バイオテクノロジー企業
  • 学術研究機関
  • 医薬品開発業務受託機関（CRO）
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • Danaher Corporation
    • 企業概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 製品販売の実績・予測
      • 製品販売量
    • 財務概要
      • 企業の収益
      • 収益シェア：地域別
      • 収益予測
    • 主な動向
      • 企業合併・買収 (M&A)
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • PerkinElmer, Inc
  • Agilent Technologies, Inc
  • Sartorius AG
  • Thermo Fisher Scientific Inc
  • Corning Incorporated
  • Bruker Corporation
  • HORIBA, Ltd.
  • Reichert, Inc
  • Malvern Panalytical Ltd
  • Similar data will be provided for each market player.
  • Attana AB
    • パイプライン製品の概要
    • 製品の主要業績評価指標（KPI）
    • 主な活動
    • 市場参入のタイムライン
    • 製品普及率
    • 売上高の推定と予測
  • Nicoya
  • Unchained Labs
  • Nanotemper Technologies GmbH
  • Creoptix AG
  • 各市場参入企業に対しても同様のデータが提供されます。

第13章 付録

目次
Product Code: BT9289

The Global Label-Free detection market reached US$ 644.83 million in 2024 and is expected to reach US$ 1,251.49 million by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.

Label-free detection is an advanced analytical technique that measures changes in the physical properties of molecules without the need for fluorescent, radioactive, or enzymatic labels. It provides real-time data on binding kinetics, affinity, and concentration, making it widely used in drug discovery, lead optimization, and biopharmaceutical research. It streamlines workflows, reduces assay development time, and allows for the analysis of complex biological samples with minimal sample preparation.

Market Dynamics: Drivers & Restraints

Growing Demand for Advanced Drug Discovery and Development Processes

The label-free detection market is driven by the increasing demand for advanced drug discovery and development processes. Pharmaceutical and biotechnology companies prefer these technologies for real-time, accurate measurement of biomolecular interactions, improving data quality and reducing label interference. The focus on biopharmaceuticals, biosimilars, and personalized medicine has accelerated the adoption of these technologies, enabling detailed analysis of complex biological molecules and targeted therapies.

Moreover, Label-free detection technologies are revolutionizing drug discovery by providing biologically relevant data with reduced artifacts. These methods eliminate the need for dyes, tags, or genetically modified cells, allowing for native cells and a more accurate representation of biological interactions. They also offer enhanced sensitivity, real-time kinetics, and multi-target profiling. Applications include phenotypic screening, target identification and validation, hit-to-lead optimization, and toxicity assessment.

Limited Sensitivity and Detection Range

Label-free detection technologies face challenges in the market due to their limited sensitivity and detection range. These systems offer real-time analysis but can be compromised when detecting low-abundance biomolecules or weak molecular interactions, especially in complex biological samples. This affects accuracy and reliability in critical applications like early-stage biomarker discovery, diagnostics, and drug screening. Traditional labeled detection methods may still be preferred, potentially limiting the adoption of label-free technologies in ultra-sensitive detection applications.

Segment Analysis

The global label-free detection market is segmented based on product type, technology, application, end user, and region.

The instruments in the product type segment are expected to dominate with the highest market share.

Instruments are crucial in the label-free detection, enabling the real-time study of biomolecular interactions. Advanced instruments like SPR analyzers, BLI systems, and ITC devices accurately measure binding kinetics, affinity, and thermodynamics without fluorescent or radioactive labels. Due to their rapid, reliable, and label-free results, these instruments are increasingly used in drug discovery, lead optimization, and biopharmaceutical development. Innovation in design, automation, and sensitivity enhancement is increasing demand across pharmaceutical, biotechnology, and research sectors.

For instance, in October 2024, Max Planck Institute researchers developed a method for precisely detecting small liquid quantities, down to micromolar levels, with exceptional sensitivity in the near-infrared spectrum. This breakthrough opens doors to advanced, label-free bio-imaging techniques for detecting target molecules in aqueous environments, pushing biomedical applications' boundaries.

Pharmaceutical and biotechnology companies in the end-user segment are the dominating with the highest market share.

The global label-free detection market is primarily driven by pharmaceutical and biotechnology companies, who rely on these technologies for drug discovery, biotherapeutics development, and biologics research. These companies use label-free systems for high-throughput screening, complex biological interactions analysis, and real-time data generation without labeling interferences. As the pharmaceutical industry shifts towards precision medicine, biologics, and small molecule therapeutics, demand for label-free detection technologies is expected to surge, solidifying their position as a primary growth driver.

Geographical Analysis

North America is expected to hold a significant position in the label-free detection market share

North America holds a substantial position in the label-free detection market due to the presence of a robust pharmaceutical and biotechnology sector, significant research investments, and prominent players like Danaher Corporation, Thermo Fisher Scientific, and Agilent Technologies. Also, the region's focus on drug discovery, early technology adoption, and government support for life sciences research fuel market growth. Market players' innovation in the region is a key driver for market growth in North America.

For instance, in February 2024, Agilent Technologies integrated the xCELLigence RTCA HT platform with the BioTek BioSpa 8 Automated Incubator, providing a non-invasive, label-free, kinetic readout of cell proliferation and cytotoxicity, thereby increasing throughput and decreasing sample sizes.

Competitive Landscape

The major global players in the label-free detection market include Danaher Corporation, PerkinElmer, Inc, Agilent Technologies, Inc, Sartorius AG, Thermo Fisher Scientific Inc, Corning Incorporated, Bruker Corporation, HORIBA, Ltd, Reichert, Inc, and Malvern Panalytical Ltd, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Label-Free Detection market report delivers a detailed analysis with 61 key tables, more than 59 visually impactful figures, and 220 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Product Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Demand for Advanced Drug Discovery and Development Processes
    • 4.1.2. Restraints
      • 4.1.2.1. Limited Sensitivity and Detection Range
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Forces Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Instruments*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Consumables
  • 6.4. Software and Services

7. By Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index, By Technology
  • 7.2. Surface Plasmon Resonance (SPR)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bio-layer interferometry (BLI)
  • 7.4. Isothermal Titration Calorimetry (ITC)
  • 7.5. Differential Scanning Calorimetry (DSC)
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Drug Discovery and Development*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Binding Kinetics and Thermodynamics
  • 8.4. Hit Confirmation and Lead Generation
  • 8.5. Endogenous Receptor Detection
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Pharmaceutical and Biotechnology Companies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Academic and Research Institutes
  • 9.4. Contract Research Organizations (CROs)
  • 9.5. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. Danaher Corporation*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals, etc.
    • 12.1.5. SWOT Analysis
  • 12.2. PerkinElmer, Inc
  • 12.3. Agilent Technologies, Inc
  • 12.4. Sartorius AG
  • 12.5. Thermo Fisher Scientific Inc
  • 12.6. Corning Incorporated
  • 12.7. Bruker Corporation
  • 12.8. HORIBA, Ltd.
  • 12.9. Reichert, Inc
  • 12.10. Malvern Panalytical Ltd
  • Similar data will be provided for each market player.

Emerging Market Players

  • 12.11. Attana AB*
    • 12.11.1. Pipeline Products Description
    • 12.11.2. Product Key Performance Indicators (KPIs)
    • 12.11.3. Key Activities
    • 12.11.4. Market Entry Timelines
    • 12.11.5. Product Penetration Rate
    • 12.11.6. Sales Estimation and Projections
  • 12.12. Nicoya
  • 12.13. Unchained Labs
  • 12.14. Nanotemper Technologies GmbH
  • 12.15. Creoptix AG
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us